Tag Archives: request

LinkedIn Needs To Boost Traction With Q4 Earnings Report

LinkedIn ( LNKD ) is set to report earnings after the close Thursday as it seeks to boost mobile user growth and usage among small and midsize businesses. The social networking site for professionals is expected to report revenue of $857.6 million, up 33% from the year-earlier quarter.  In Q3, year-over-year sales rose 37%. The consensus estimate on earnings per share minus items, based on analysts polled by Thomson Reuters, is 78 cents, up 28% but a slowdown from 50% year-over-year growth in Q3. RBC Capital Markets analyst Mark Mahaney on Tuesday reiterated an outperform rating on LinkedIn with a price target of 300. LinkedIn stock was up about 1% in afternoon trading on the stock market today . It closed down 6% Wednesday at 191.25, about 26% off a nine-month high above 258 touched on Nov. 12. LinkedIn stock fell below its 10-week moving average in late December. “LinkedIn’s fundamentals are the strongest of any large-cap Internet stock,” Mahaney wrote. In December, LinkedIn rolled out its new mobile app, Voyager, designed to be faster and more intuitive for users. “We believe this app could lead to greater engagement on the service and will be listening to the Q4 call for any mention of the product’s performance,” Mahaney wrote. LinkedIn eased concerns of slowing growth when it reported third-quarter earnings on Oct. 29 that topped expectations. LinkedIn ended the quarter with 396 million members, up 20% from Q3 2104. The stock popped 11% the day after. “We interpret this intraquarter share price performance as implying slightly negative expectations going into fourth-quarter earnings,” Mahaney wrote. The company has three revenue streams. Talent Solutions, used by companies to recruit employees, accounted for 64% of revenue in Q3. Marketing Solutions, which sells ads, accounted for 18%. Premium Subscriptions, fees paid by users for enhanced services, accounted for the other 18%. LinkedIn gets a strong Composite Rating of 90 from IBD out of a possible 99. Facebook ( FB ) continued to show it’s king of social media with a fourth-quarter earnings report last week that soundly beat expectations on booming mobile ad revenue. Facebook revenue rose 52% to $5.84 billion from the year-earlier period. Monthly active users on Facebook came in at 1.59 billion. Twitter ( TWTR ) is set to report earnings after the close on Feb. 10. Twitter stock has lost about 60% of its value in the past 12 months on worries about slowing user growth and rising competition for online ad revenue.

Imperva Topples On Mixed Guidance But Clobbers Q4 Expectations

Cybersecurity firm Imperva ( IMPV ) topped analysts’ Q4 views, but its strangled current-quarter and 2016 guidance sent its shares to nose-diving to a 10-month low on Wall Street Thursday. Imperva stock was down 14% in midday trading on the stock market today , near 42.50, earlier falling as low as 41.81, after the company’s late Wednesday earnings report. At least four analysts cut their price targets on Imperva stock. For Q4, Imperva reported 20 cents earnings per share ex items on $72.7 million in sales, topping analysts projections for 15 cents and $68.1 million, and topping the company’s earlier view for 10-16 cents and $66 million to $68 million. Sales rose 41% year over year, and EPS minus items swung from a four-cent loss in the year-earlier quarter. Imperva wrapped up the year with $234.3 million in sales, up 43%, and 11 cents EPS ex items, swinging from a 74-cent loss in 2014. Both measures beat Wall Street expectations and the company’s forecast three months ago. Imperva’s Q1 Losses Expected To Deepen Current-quarter and 2016 guidance was a mixed bag. For Q1, Imperva sees $58 million to $60 million in sales and a 26-32 loss per share ex items. The sales view roughly met the consensus for $59.8 million, but Wall Street was expecting losses of just 11 cents a share ex items. On a year-over-year basis, Q1 sales would be up 32% at the midpoint of guidance, but losses would stagnate or deepen from 26 cents in the year-earlier quarter. Imperva guided 2016 sales at $302 million to $307 million, which would be up 30% at the midpoint. In September, Imperva saw 25% growth in 2016. But the EPS ex items view for 20 cents missed the consensus model for 30 cents, Summit Research analyst Srini Nandury wrote in a research report. Nandury and Piper Jaffray analyst Andrew Nowinski separately blamed the guidance flop on Imperva’s plan to invest more heavily in sales and marketing as well as research and development to gain market share. Both expect that Imperva’s guidance was conservative. Major breaches drove massive growth in earlier quarters and years, Nowinski wrote in a research report. But that “panic buying” has slowed, he says. “It is becoming clear that in the absence of ‘panic buying,’ the security space can still deliver strong top-line growth, but that growth will come at a higher-than-expected cost,” he wrote. Nowinski maintained his overweight rating on Imperva stock but slashed his price target to 54 from 84. Nandury dropped his price target to 70 from 80 but reiterated a buy rating on Imperva stock. Subscription Sales Drive Top Line Subscription revenue of $14.9 million, up 105%, drove Imperva’s top line, Nowinski wrote. The number of $100,000-plus deals grew 15.4% vs. the year-earlier quarter, “and the company did more seven-figure deals than in the entire history of the company.” William Blair analyst Jonathan Ho suggested long-term investors take advantage of Imperva’s stock weakness. Imperva stock is down 33% in 2016. “The fundamentals appear strong,” Ho wrote in a report. “However, we concede there will likely be some continued short-term volatility for security stocks in general due to challenging market conditions.” IBD’s 26-company Computer Software-Security industry group was down 2% midday Thursday and is down 20% for the year, earlier in the day touching a 16-month low.  Palo Alto Networks ( PANW ) and CyberArk Software ( CYBR ) lead the group with Composite Ratings of 81 and 80, respectively, out of a best-possible 99. Imperva stock has a CR of 47. Image provided by Shutterstock .

Abiomed, Boston Scientific Move Opposite Ways On Quarterly Reports

Medical device maker Abiomed ( ABMD ) popped in early trading after it beat quarterly estimates and raised guidance Thursday, while its larger counterpart Boston Scientific ( BSX ) was falling after a more mixed report. Abiomed’s earnings for its fiscal Q3 ended Dec. 31 totaled 23 cents a share, down 23% from the year-earlier quarter but well ahead of analysts’ consensus of 15 cents as reported by Thomson Reuters. Sales rose 38% to $85.8 million, about $5 million above consensus. Abiomed raised its revenue guidance for the full fiscal 2016 to $326 million, up from a previous range of $305 million to $315 million. It said that sales in the current quarter should be $90 million, above Wall Street’s estimate of $85.1 million and up from $62.6 million in last year’s fourth quarter. The company didn’t guide earnings, but it did say that gross profit margin should be higher than its previous guidance of 15% to 17%. Abiomed stock was up 5% in morning trading on the stock market today , near 89. The news wasn’t a total surprise, since Abiomed issued preliminary Q3 sales last month that matched the current report. Leerink analyst Danielle Antalffy wrote that the EPS and guidance numbers brought further upside, supporting strong uptake of Abiomed’s Impella heart pump. “In the U.S., Abiomed clearly continues to drive what we believe is sustainable adoption momentum that should continue to ramp with the recent Impella 2.5 PMA (premarket approval), as the company can more aggressively market to physicians than before,” Antalffy wrote in a research note. “This is further supplemented by the Impella RP and upcoming late-calendar-year 2016 Japan regulatory and reimbursement approval.” Boston Scientific Revenue Falls Short Boston Scientific stock was down 4% Thursday morning, near 17, after the company reported Q4 sales of $1.98 billion, up 5% from the prior year’s Q4 but about $16 million below consensus. Profit rose 18% to 26 cents a share, a penny over the Street. Boston Scientific said that sales in the current quarter should be $1.89 billion to $1.94 billion, somewhat on the low side of analysts’ $1.93 billion consensus, though up from $1.77 billion last year. It said earnings will be 23 to 25 cents a share, in line with consensus and up from 21 cents last year. For the year, the company’s sales guidance of $7.9 billion to $8.1 billion bracketed consensus, while EPS was on the high side at $1.03 to $1.07. “Gross margins (in Q4) came in slightly above our expectations, but operating expenses came in well above our estimate driven by higher sales, general and administrative and R&D expenses, that were offset by tax (which we estimate contributed 1 to 2 cents),” Evercore ISI analyst Vijay Kumar wrote in an email to clients. “Overall, in the context of a tough health care tape and concerns over slowdown in emerging markets and ICD (implantable cardioverter defibrillator) share losses, we view today’s print and guidance as solid.” Image provided by Shutterstock .